Member Info for Mumbo_Jumbo

I don’t believe there ever was a serious offer of any kind and that too with someone on the Board… why this charade was plated out and for whose benefit.

One of the BOD walking away…. Maybe didn’t like what he was seeing.

That’s because Hydrogen got banned :)

jolly - they need to raise urgently, won't go beyond last quarter.

Elderlybird ... you raise a very interesting question and it is this very reason why big Pharma have never been interested in putting the same effort in developing new antibiotics..... a quick cheap cure isn't very profitable compared to an expensive long protracted treatment.

Having said that, very few cancers are "curable"... majority are more like how long you have left. Early and continuous monitoring could pave the way for more targeted therapies that may increase your life expectancy and moreover the quality of life during much of this period.

I am not an investor here yet, but I have been in the past almost 10 years or so ago when ANGLE went down this path.

Fell off my radar…. And noticed the news a bit late.

Expected it to rise a lot more.

Move to your bank if they deal in shares. Should give you bit more peace of mind and not worry about broker doing fraud and not segregated the pots.

And how much are they in profit already?

What do they know that we don’t….. funding maybe?

Be in Cash or short the nasdaq. It will go sub 10K this year.

Hydro and Costa,

I commented on his strategy which has seen him take a huge hair cut in his profits in the last year, which he needn't have done. "If you don't need money for few years" and parking it for years may or may not yield a positive outcome, indeed it more often will have cost you opportunities elsewhere. He will not get to the highs of 38p ever or until production or an offer comes in few years down the line, say 2024. Then all he would have done is basically catch up with the profit he had given up on 3 or 4 years earlier and not grown that. Had he sold in the 30s in 2020/20221, he could have reinvested that elsewhere or even here now and be far more richer when 2024 comes round, providing everything goes well.

Getting married to an AIM stock is sure way to kill your capital over the long term, there is a max mcap a non cash generating stock will reach and that's where you have to play it with your investment strategy.

GGP is headed to sub 10 on the valuation of 5% that NCM will attach to it. It was obvious 6 months ago that it will be the case and so it's proving to be so far. Infact I had over estimated what NCM will pay back then but now I believe it will not be paying more than $50-60 million....

Gym boy - assuming what you say is true then you have staggeringly naive investment strategy.

Written this off… you win some and lose some. Bought in at 20p+.

Sang - you invested here?

what happened here Bojo? Seemingly had everything going for itself when I was looking at it year or so back.

You didn’t buy in 20s? Oh well, don’t worry you will get your chance again.

Phil - I told you months ago, I would not short 4d. Nasdaq is the place for it generally. Pick some of the over priced tech share.

I hope you made back some of your losses from SNG. Called it months before that covid was coming to an end as we know it as well as the vaccinated population issue in the trial. Maybe just maybe I do know something in this area.

You will always be buying this cheaper eventually. Don’t forget there will be another round of dilution pretty soon.

Phil then why is it still in the 50s. Most of you are still under heavy water…… This is only a low bar to get it passed to next stage, fraction of a fraction. Overall it’s 4 out of 47 so far.

Must be a stupid man for selling out ….. or is he.

Roselow, overall 4/47 to data. Once focus shifts to RCC then it will be a different ball game of end points.

Phil - No I am not. What about rest of the data? Its a dud in all others?

occurs to me that overall they have not met the end point in the 47 patients they have recruited so far. A very low bar of 10% was set and to date its not been met in all the patients they have recruited thus far.